Health economic analysis of bevacizumab + paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast cancer

Health economic analysis of bevacizumab + paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast cancer /

Background The Norwegian Knowledge Centre for the Health Services has been commissioned by Norwegian Directorate of Health's Cancer Programme to make an assessment of the cost per progression-free year gained associated with the use of bevacizumab in combination with paclitaxel versus paclitaxe...

Full description

Saved in:
Bibliographic Details
Online Access: Full text
Main Authors: Movik, Espen (Author), Hamidi, Vida (Author), Natvig Norderhaug, Inger (Author), Klemp, Marianne (Author)
Format: Electronic eBook
Language:English
Published: Oslo : Norwegian Knowledge Centre for the Health Services, 2009
Subjects:
Breast Neoplasms > drug therapy.
Breast Neoplasms > secondary.
Bevacizumab > economics.
Paclitaxel > economics.
Drug Therapy, Combination.
Cost-Benefit Analysis.
Norway.

Internet

Full text

Similar Items